Company
South KoreaHanAll BioPharma Co., Ltd. is a leading Korean pharmaceutical company focused on drug delivery, biotherapeutics, and new small molecule discovery.
Private/Public:
public
Phone:02-550-8800
Fax:02-550-8400
Email:[email protected]
Website:http://en.hanall.co.kr/main
Address:Daewoong Building FL9, 12 Bongeunsaro 114-gil, Gangnam-gu, Seoul, South Korea
1973
Since
1
Country
0
Top Service Category
0
Sub-Service Category
Top Services
South Korea
- (06.Sep.2021) Hanall Biopharma Aims to Be Global Blockbuster Drug Developer
- (01.Sep.2021) Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China
- (01.Sep.2021) Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China
- (19.Aug.2021) Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics
- (29.Jul.2021) Daewoong, Hanall Invest in NurrOn Pharmaceuticals for Collaboration in US
- (29.Jul.2021) HanAll Biopharma Reports Second Quarter 2021 Results
- (23.Jul.2021) Hanall Biopharma Seeks FDA's Nod for Dry Eye Treatment
- (16.Jul.2021) Harbour BioMed Announces Last Patient Dosing of Phase1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder
- (06.Jul.2021) Harbour BioMed Reports Positive Topline Results From Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
- (02.Jun.2021) Hanall's US Partner Resumes Clinical Trials of HL161
- (11.May.2021) Regulator Disciplines HanAll for Manipulating Drug Stability Data
- (06.May.2021) HanAll Biopharma Announces First Quarter 2021 Results
- (06.May.2021) HanAll Biopharma Reports First Quarter 2021 Financial Results
- (03.May.2021) ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis
- (11.Mar.2021) Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial
- (09.Feb.2021) FDA Deems Hanall Biopharma's Dry Eye Treatment Trial 'Acceptable'
- (08.Feb.2021) ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation From U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
- (27.Jan.2021) Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients With Myasthenia Gravis
- (19.Jan.2021) Hanall Biopharma, Net Profit in 2020 Increased by 14% from the Previous Year to KRW 21.9 Billion
- (12.Jan.2021) Immunovant Provides Corporate Update
- (16.Nov.2020) Harbour BioMed Will Present Results From Its Phase II Clinical Trial With Tanfanercept (HBM9036) in Patients With Moderate-To-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society
- (30.Sep.2020) Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia